1
|
Hattori M, Kinoshita K, Saito A, Yamamoto S. Exogenous oxytocin increases gaze to humans in male cats. Sci Rep 2024; 14:8953. [PMID: 38637547 PMCID: PMC11026458 DOI: 10.1038/s41598-024-59161-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Accepted: 04/08/2024] [Indexed: 04/20/2024] Open
Abstract
Although oxytocin (OT) plays a role in bonding between heterospecifics and conspecifics, the effects of OT on the formation of such interspecific social behavior have only been investigated between humans and dogs (Canis familiaris). In this study, for comparative evaluation of the effects of OT between dog-human and cat-human social interaction, we investigated the effects of exogenous OT on the behavior of domestic cats (Felis silvestris catus) toward humans. We intranasally administered OT or saline to 30 cats using a nebulizer and recorded their behavior (gaze, touch, vocalization, and proximity). The results showed an interaction between the administration condition and sex for gaze duration. Post hoc analyses revealed a significant increase in gaze in the OT condition in male cats but not in females. There were no significant differences in gaze toward owners and strangers in any condition or sex. The male-specific OT-mediated increase in gaze toward humans observed in this study differs from previous research on dogs wherein such effects were observed only in females. These findings suggest an overall effect of exogenous OT on cats' social relationship with humans as well as the possibility of different mechanisms between cat-human and dog-human relationships.
Collapse
Affiliation(s)
- Madoka Hattori
- Wildlife Research Center, Kyoto University, 2-24 Tanaka-Sekiden-cho, Sakyo-ku, Kyoto, 606-8203, Japan.
| | - Kodzue Kinoshita
- Graduate School of Asian and African Area Studies, Kyoto University, Research Bldg. No 2 Yoshida-Honmachi, Sakyo-ku, Kyoto, 606-8501, Japan
| | - Atsuko Saito
- Department of Psychology, Faculty of Human Sciences, Sophia University, 7-1 Kioicho, Chiyoda-ku, Tokyo, 102-8554, Japan
| | - Shinya Yamamoto
- Wildlife Research Center, Kyoto University, 2-24 Tanaka-Sekiden-cho, Sakyo-ku, Kyoto, 606-8203, Japan.
- Institute for Advanced Study, Kyoto University, Yoshida Ushinomiya-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
| |
Collapse
|
2
|
Kuroda Y, Goto A, Sugimoto T, Fujita K, Uchida K, Matsumoto N, Shimada H, Ohtsuka R, Yamada M, Fujiwara Y, Seike A, Hattori M, Ito G, Arai H, Sakurai T. Participatory approaches for developing a practical handbook integrating health information for supporting individuals with mild cognitive impairment and their families. Health Expect 2023; 27:e13870. [PMID: 37726981 PMCID: PMC10726060 DOI: 10.1111/hex.13870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 08/30/2023] [Accepted: 09/05/2023] [Indexed: 09/21/2023] Open
Abstract
AIM This study aimed to develop a patient-centred handbook that integrates information on lifestyle modifications and psychological support strategies for individuals with mild cognitive impairment (MCI). This article provides a comprehensive record of the development process. METHODS We adopted a participatory research model for the methodology, which comprised five phases and involved an interdisciplinary team specializing in dementia and health literacy. Data were initially collected via interviews conducted among patients with MCI (n = 5) and their families (n = 5). Given the study's preliminary nature, depth and richness of the qualitative data were the key concerns for determining the sample size, rather than broad generalizability. We ensured the inclusion of diverse experiences and perspectives by facilitating the creation of patient questions (PQs) that merged scientific evidence with patient perspectives. To enhance the handbook's accessibility and utility, we continuously evaluated the same using patient interviews, health literacy tool assessments and team discussions. This comprehensive approach harmonized scientific knowledge and patient experience, leading to the development of a personalized MCI management guide. RESULTS The handbook comprises nine domains, encompassing 38 selected PQs: MCI, lifestyle, lifestyle-related diseases, exercise, nutrition, social participation, cognitive training, psychological care and family support. The health literacy handbook was evaluated based on Clear Communication Index scores. The results revealed that 73.7% of the PQs were deemed difficult prerevision, whereas only 5.3% remained challenging postrevision. The formative evaluation underscored the need for more detailed explanations prerevision, whereas postrevision comments focused primarily on editorial suggestions. CONCLUSION The inclusion of patients' perspectives right from the outset ensured that the handbook met their specific needs. The final version, which reflects all stakeholders' inputs, is now slated for imminent publication. PATIENT OR PUBLIC CONTRIBUTION Patients and the public participated extensively throughout the project, from initial interviews to material evaluation and refinement.
Collapse
Affiliation(s)
- Yujiro Kuroda
- Department of Prevention and Care ScienceCenter for Development of Advanced Medicine for Dementia, National Center for Geriatrics and GerontologyObuJapan
| | - Aya Goto
- Fukushima Medical University School of Medicine, Center for Integrated Science and HumanitiesFukushima Medical UniversityFukushimaJapan
| | - Taiki Sugimoto
- Department of Prevention and Care ScienceCenter for Development of Advanced Medicine for Dementia, National Center for Geriatrics and GerontologyObuJapan
| | - Kosuke Fujita
- Department of Prevention and Care ScienceCenter for Development of Advanced Medicine for Dementia, National Center for Geriatrics and GerontologyObuJapan
| | - Kazuaki Uchida
- Department of Prevention and Care ScienceCenter for Development of Advanced Medicine for Dementia, National Center for Geriatrics and GerontologyObuJapan
| | - Nanae Matsumoto
- Department of Prevention and Care ScienceCenter for Development of Advanced Medicine for Dementia, National Center for Geriatrics and GerontologyObuJapan
| | - Hiroyuki Shimada
- Department of Preventive GerontologyCenter for Gerontology and Social Science, National Center for Geriatrics and GerontologyObuJapan
| | - Rei Ohtsuka
- Department of Epidemiology of AgingCenter for Development of Advanced Medicine for Dementia, National Center for Geriatrics and GerontologyObuJapan
| | - Minoru Yamada
- Graduate School of Comprehensive Human Sciences, University of TsukubaTokyoJapan
| | - Yoshinori Fujiwara
- Research Team for Social Participation and Community HealthTokyo Metropolitan Institute of GerontologyTokyoJapan
| | - Aya Seike
- Graduate School of Sport and Health ScienceRitsumeikan UniversityKyotoJapan
| | | | - Gabin Ito
- Department of Media CreationKyoto Seika UniversityKyotoJapan
| | - Hidenori Arai
- National Center for Geriatrics and GerontologyObuJapan
| | - Takashi Sakurai
- Department of Prevention and Care ScienceCenter for Development of Advanced Medicine for Dementia, National Center for Geriatrics and GerontologyObuJapan
| |
Collapse
|
3
|
Takagi S, Koyasu H, Hattori M, Nagasawa T, Maejima M, Nagasawa M, Kikusui T, Saito A. Effects of the COVID-19 Pandemic on the Behavioural Tendencies of Cats and Dogs in Japan. Animals (Basel) 2023; 13:2217. [PMID: 37444015 DOI: 10.3390/ani13132217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2023] [Revised: 06/27/2023] [Accepted: 07/03/2023] [Indexed: 07/15/2023] Open
Abstract
Physical and mental effects stemming from COVID-19 have impacted not only people's lives but also the lives of their pets, which in recent years are often seen as members of the family. This study aimed to explore the impact of the COVID-19 pandemic in Japan on pets and their owners. Participants reported changes in physical activity and mental health, as well as working conditions and frequency of interaction with pets, before and after behavioural restrictions due to the COVID-19 pandemic. We also asked about their pets' behaviours using the Feline Behavioural Assessment and Research Questionnaire (Fe-BARQ) and the Canine Behavioural Assessment and Research Questionnaire (C-BARQ). This study showed that most cat and dog owners spent more time at home due to the COVID-19 behavioural restrictions and that the frequency of contact interaction with their pets increased. However, this study showed higher stress-related behaviours (e.g., cats: excessive grooming; dogs: aggression towards owners) among pets whose owners increased contact interaction. Furthermore, owners' low mental health was correlated with high stress-related behaviours (e.g., touch sensitivity) in pets. The results of this study indicate that the lockdown caused by the COVID-19 pandemic in Japan may have affected not only the lives of owners but also the interaction between owners and their pets, and consequently their pets' behaviours. Therefore, there is also concern that changes in lifestyle patterns caused by pandemics could form a negative feedback loop between the health status of both owners and their pets.
Collapse
Affiliation(s)
- Saho Takagi
- Department of Animal Science and Biotechnology, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara 252-5201, Japan
- Japan Society for the Promotion of Science, Kojimachi Business Center Building, 5-3-1 Kojimachi, Chiyoda-ku, Tokyo 102-0083, Japan
| | - Hikari Koyasu
- Department of Animal Science and Biotechnology, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara 252-5201, Japan
| | - Madoka Hattori
- Department of Animal Science and Biotechnology, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara 252-5201, Japan
- Wildlife Research Center, Kyoto University, 2-24 Tanaka-Sekiden-cho, Sakyo-ku, Kyoto 606-8203, Japan
| | - Takumi Nagasawa
- Department of Animal Science, Graduate School of Agriculture, Tokyo University of Agriculture, Funako 1737, Atsugi 243-0034, Japan
| | - Michiro Maejima
- Graduate School of Human Sciences, Sophia University, 7-1 Kioi-cho, Chiyoda-ku, Tokyo 102-8554, Japan
| | - Miho Nagasawa
- Department of Animal Science and Biotechnology, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara 252-5201, Japan
| | - Takefumi Kikusui
- Department of Animal Science and Biotechnology, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara 252-5201, Japan
- Center for Human and Animal Symbiosis Science, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara 252-5201, Japan
| | - Atsuko Saito
- Department of Psychology, Faculty of Human Sciences, Sophia University, 7-1 Kioi-cho, Chiyoda-ku, Tokyo 102-8554, Japan
| |
Collapse
|
4
|
Yoshimura A, Nakakami A, Komaki R, Isogai A, Endo Y, Ozaki Y, Nozawa K, Kataoka A, Kotani H, Hattori M, Sawaki M, Iwata H. P289 Retrospective study of pregnancy outcome after breast cancer. Breast 2023. [DOI: 10.1016/s0960-9776(23)00407-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
|
5
|
Endo Y, Kotani H, Nakakami A, Komaki R, Isogai A, Ozaki Y, Nozawa K, Kataoka A, Yoshimura A, Hattori M, Sawaki M, Iwata H. P232 A study to evaluate the safety and utility of targeted axillary dissection using Guiding-Marker System. Breast 2023. [DOI: 10.1016/s0960-9776(23)00350-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
|
6
|
Girardi F, Matz M, Stiller C, You H, Marcos Gragera R, Valkov MY, Bulliard JL, De P, Morrison D, Wanner M, O'Brian DK, Saint-Jacques N, Coleman MP, Allemani C, Hamdi-Chérif M, Kara L, Meguenni K, Regagba D, Bayo S, Cheick Bougadari T, Manraj SS, Bendahhou K, Ladipo A, Ogunbiyi OJ, Somdyala NIM, Chaplin MA, Moreno F, Calabrano GH, Espinola SB, Carballo Quintero B, Fita R, Laspada WD, Ibañez SG, Lima CA, Da Costa AM, De Souza PCF, Chaves J, Laporte CA, Curado MP, de Oliveira JC, Veneziano CLA, Veneziano DB, Almeida ABM, Latorre MRDO, Rebelo MS, Santos MO, Azevedo e Silva G, Galaz JC, Aparicio Aravena M, Sanhueza Monsalve J, Herrmann DA, Vargas S, Herrera VM, Uribe CJ, Bravo LE, Garcia LS, Arias-Ortiz NE, Morantes D, Jurado DM, Yépez Chamorro MC, Delgado S, Ramirez M, Galán Alvarez YH, Torres P, Martínez-Reyes F, Jaramillo L, Quinto R, Castillo J, Mendoza M, Cueva P, Yépez JG, Bhakkan B, Deloumeaux J, Joachim C, Macni J, Carrillo R, Shalkow Klincovstein J, Rivera Gomez R, Perez P, Poquioma E, Tortolero-Luna G, Zavala D, Alonso R, Barrios E, Eckstrand A, Nikiforuk C, Woods RR, Noonan G, Turner D, Kumar E, Zhang B, Dowden JJ, Doyle GP, Saint-Jacques N, Walsh G, Anam A, De P, McClure CA, Vriends KA, Bertrand C, Ramanakumar AV, Davis L, Kozie S, Freeman T, George JT, Avila RM, O’Brien DK, Holt A, Almon L, Kwong S, Morris C, Rycroft R, Mueller L, Phillips CE, Brown H, Cromartie B, Ruterbusch J, Schwartz AG, Levin GM, Wohler B, Bayakly R, Ward KC, Gomez SL, McKinley M, Cress R, Davis J, Hernandez B, Johnson CJ, Morawski BM, Ruppert LP, Bentler S, Charlton ME, Huang B, Tucker TC, Deapen D, Liu L, Hsieh MC, Wu XC, Schwenn M, Stern K, Gershman ST, Knowlton RC, Alverson G, Weaver T, Desai J, Rogers DB, Jackson-Thompson J, Lemons D, Zimmerman HJ, Hood M, Roberts-Johnson J, Hammond W, Rees JR, Pawlish KS, Stroup A, Key C, Wiggins C, Kahn AR, Schymura MJ, Radhakrishnan S, Rao C, Giljahn LK, Slocumb RM, Dabbs C, Espinoza RE, Aird KG, Beran T, Rubertone JJ, Slack SJ, Oh J, Janes TA, Schwartz SM, Chiodini SC, Hurley DM, Whiteside MA, Rai S, Williams MA, Herget K, Sweeney C, Kachajian J, Keitheri Cheteri MB, Migliore Santiago P, Blankenship SE, Conaway JL, Borchers R, Malicki R, Espinoza J, Grandpre J, Weir HK, Wilson R, Edwards BK, Mariotto A, Rodriguez-Galindo C, Wang N, Yang L, Chen JS, Zhou Y, He YT, Song GH, Gu XP, Mei D, Mu HJ, Ge HM, Wu TH, Li YY, Zhao DL, Jin F, Zhang JH, Zhu FD, Junhua Q, Yang YL, Jiang CX, Biao W, Wang J, Li QL, Yi H, Zhou X, Dong J, Li W, Fu FX, Liu SZ, Chen JG, Zhu J, Li YH, Lu YQ, Fan M, Huang SQ, Guo GP, Zhaolai H, Wei K, Chen WQ, Wei W, Zeng H, Demetriou AV, Mang WK, Ngan KC, Kataki AC, Krishnatreya M, Jayalekshmi PA, Sebastian P, George PS, Mathew A, Nandakumar A, Malekzadeh R, Roshandel G, Keinan-Boker L, Silverman BG, Ito H, Koyanagi Y, Sato M, Tobori F, Nakata I, Teramoto N, Hattori M, Kaizaki Y, Moki F, Sugiyama H, Utada M, Nishimura M, Yoshida K, Kurosawa K, Nemoto Y, Narimatsu H, Sakaguchi M, Kanemura S, Naito M, Narisawa R, Miyashiro I, Nakata K, Mori D, Yoshitake M, Oki I, Fukushima N, Shibata A, Iwasa K, Ono C, Matsuda T, Nimri O, Jung KW, Won YJ, Alawadhi E, Elbasmi A, Ab Manan A, Adam F, Nansalmaa E, Tudev U, Ochir C, Al Khater AM, El Mistiri MM, Lim GH, Teo YY, Chiang CJ, Lee WC, Buasom R, Sangrajrang S, Suwanrungruang K, Vatanasapt P, Daoprasert K, Pongnikorn D, Leklob A, Sangkitipaiboon S, Geater SL, Sriplung H, Ceylan O, Kög I, Dirican O, Köse T, Gurbuz T, Karaşahin FE, Turhan D, Aktaş U, Halat Y, Eser S, Yakut CI, Altinisik M, Cavusoglu Y, Türkköylü A, Üçüncü N, Hackl M, Zborovskaya AA, Aleinikova OV, Henau K, Van Eycken L, Atanasov TY, Valerianova Z, Šekerija M, Dušek L, Zvolský M, Steinrud Mørch L, Storm H, Wessel Skovlund C, Innos K, Mägi M, Malila N, Seppä K, Jégu J, Velten M, Cornet E, Troussard X, Bouvier AM, Guizard AV, Bouvier V, Launoy G, Dabakuyo Yonli S, Poillot ML, Maynadié M, Mounier M, Vaconnet L, Woronoff AS, Daoulas M, Robaszkiewicz M, Clavel J, Poulalhon C, Desandes E, Lacour B, Baldi I, Amadeo B, Coureau G, Monnereau A, Orazio S, Audoin M, D’Almeida TC, Boyer S, Hammas K, Trétarre B, Colonna M, Delafosse P, Plouvier S, Cowppli-Bony A, Molinié F, Bara S, Ganry O, Lapôtre-Ledoux B, Daubisse-Marliac L, Bossard N, Uhry Z, Estève J, Stabenow R, Wilsdorf-Köhler H, Eberle A, Luttmann S, Löhden I, Nennecke AL, Kieschke J, Sirri E, Justenhoven C, Reinwald F, Holleczek B, Eisemann N, Katalinic A, Asquez RA, Kumar V, Petridou E, Ólafsdóttir EJ, Tryggvadóttir L, Murray DE, Walsh PM, Sundseth H, Harney M, Mazzoleni G, Vittadello F, Coviello E, Cuccaro F, Galasso R, Sampietro G, Giacomin A, Magoni M, Ardizzone A, D’Argenzio A, Di Prima AA, Ippolito A, Lavecchia AM, Sutera Sardo A, Gola G, Ballotari P, Giacomazzi E, Ferretti S, Dal Maso L, Serraino D, Celesia MV, Filiberti RA, Pannozzo F, Melcarne A, Quarta F, Andreano A, Russo AG, Carrozzi G, Cirilli C, Cavalieri d’Oro L, Rognoni M, Fusco M, Vitale MF, Usala M, Cusimano R, Mazzucco W, Michiara M, Sgargi P, Boschetti L, Marguati S, Chiaranda G, Seghini P, Maule MM, Merletti F, Spata E, Tumino R, Mancuso P, Cassetti T, Sassatelli R, Falcini F, Giorgetti S, Caiazzo AL, Cavallo R, Piras D, Bella F, Madeddu A, Fanetti AC, Maspero S, Carone S, Mincuzzi A, Candela G, Scuderi T, Gentilini MA, Rizzello R, Rosso S, Caldarella A, Intrieri T, Bianconi F, Contiero P, Tagliabue G, Rugge M, Zorzi M, Beggiato S, Brustolin A, Gatta G, De Angelis R, Vicentini M, Zanetti R, Stracci F, Maurina A, Oniščuka M, Mousavi M, Steponaviciene L, Vincerževskienė I, Azzopardi MJ, Calleja N, Siesling S, Visser O, Johannesen TB, Larønningen S, Trojanowski M, Macek P, Mierzwa T, Rachtan J, Rosińska A, Kępska K, Kościańska B, Barna K, Sulkowska U, Gebauer T, Łapińska JB, Wójcik-Tomaszewska J, Motnyk M, Patro A, Gos A, Sikorska K, Bielska-Lasota M, Didkowska JA, Wojciechowska U, Forjaz de Lacerda G, Rego RA, Carrito B, Pais A, Bento MJ, Rodrigues J, Lourenço A, Mayer-da-Silva A, Coza D, Todescu AI, Valkov MY, Gusenkova L, Lazarevich O, Prudnikova O, Vjushkov DM, Egorova A, Orlov A, Pikalova LV, Zhuikova LD, Adamcik J, Safaei Diba C, Zadnik V, Žagar T, De-La-Cruz M, Lopez-de-Munain A, Aleman A, Rojas D, Chillarón RJ, Navarro AIM, Marcos-Gragera R, Puigdemont M, Rodríguez-Barranco M, Sánchez Perez MJ, Franch Sureda P, Ramos Montserrat M, Chirlaque López MD, Sánchez Gil A, Ardanaz E, Guevara M, Cañete-Nieto A, Peris-Bonet R, Carulla M, Galceran J, Almela F, Sabater C, Khan S, Pettersson D, Dickman P, Staehelin K, Struchen B, Egger Hayoz C, Rapiti E, Schaffar R, Went P, Mousavi SM, Bulliard JL, Maspoli-Conconi M, Kuehni CE, Redmond SM, Bordoni A, Ortelli L, Chiolero A, Konzelmann I, Rohrmann S, Wanner M, Broggio J, Rashbass J, Stiller C, Fitzpatrick D, Gavin A, Morrison DS, Thomson CS, Greene G, Huws DW, Grayson M, Rawcliffe H, Allemani C, Coleman MP, Di Carlo V, Girardi F, Matz M, Minicozzi P, Sanz N, Ssenyonga N, James D, Stephens R, Chalker E, Smith M, Gugusheff J, You H, Qin Li S, Dugdale S, Moore J, Philpot S, Pfeiffer R, Thomas H, Silva Ragaini B, Venn AJ, Evans SM, Te Marvelde L, Savietto V, Trevithick R, Aitken J, Currow D, Fowler C, Lewis C. Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). Neuro Oncol 2023; 25:580-592. [PMID: 36355361 PMCID: PMC10013649 DOI: 10.1093/neuonc/noac217] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology. METHODS We analyzed individual data for adults (15-99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000-2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator. RESULTS The study included 556,237 adults. In 2010-2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%-38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000-2004 and 2005-2009. These improvements were more noticeable among adults diagnosed aged 40-70 years than among younger adults. CONCLUSIONS To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines.
Collapse
Affiliation(s)
- Fabio Girardi
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.,Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK.,Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Melissa Matz
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
| | - Charles Stiller
- National Cancer Registration and Analysis Service, Public Health England, London, UK
| | - Hui You
- Cancer Information Analysis Unit, Cancer Institute NSW, St Leonards, New South Wales, Australia
| | - Rafael Marcos Gragera
- Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona, Spain
| | - Mikhail Y Valkov
- Department of Radiology, Radiotherapy and Oncology, Northern State Medical University, Arkhangelsk, Russia
| | - Jean-Luc Bulliard
- Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.,Neuchâtel and Jura Tumour Registry, Neuchâtel, Switzerland
| | - Prithwish De
- Surveillance and Cancer Registry, and Research Office, Clinical Institutes and Quality Programs, Ontario Health, Toronto, Ontario, Canada
| | - David Morrison
- Scottish Cancer Registry, Public Health Scotland, Edinburgh, UK
| | - Miriam Wanner
- Cancer Registry Zürich, Zug, Schaffhausen and Schwyz, University Hospital Zürich, Zürich, Switzerland
| | - David K O'Brian
- Alaska Cancer Registry, Alaska Department of Health and Social Services, Anchorage, Alaska, USA
| | - Nathalie Saint-Jacques
- Department of Medicine and Community Health and Epidemiology, Centre for Clinical Research, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Michel P Coleman
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.,Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK
| | - Claudia Allemani
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Hattori M, Saito A, Nagasawa M, Kikusui T, Yamamoto S. Changes in Cat Facial Morphology Are Related to Interaction with Humans. Animals (Basel) 2022; 12:ani12243493. [PMID: 36552413 PMCID: PMC9774281 DOI: 10.3390/ani12243493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Revised: 12/03/2022] [Accepted: 12/05/2022] [Indexed: 12/14/2022] Open
Abstract
We aimed to clarify the changes in facial morphology of cats in relation to their interactions with humans. In Study 1, we compared the facial morphology of cats (feral mixed breed, owned domestic mixed breed, and owned domestic purebreds) with that of African wildcats. After collecting 3295 photos, we found that owned domestic cats' noses were significantly shorter than those of African wildcats and feral mixed breed, and there were no significant differences between the latter two. The eye angles were significantly more gradual in owned domestic purebreds than in the other groups. In Study 2, we examined the correlation between facial morphology and years with the owner, and found that the former is not affected by the latter. This suggests that changes in facial morphology are possibly transgenerational changes. The difference in facial morphology between wildcats and owned cats might be caused by domestication, and that between feral cats and owned cats might be due to feralization. In Study 3, we investigated whether cats' facial features affect cuteness ratings. We asked human participants to evaluate the cuteness of cats' face images and found that faces with shorter nose lengths were considered cuter. This suggests that owned domestic cats' facial morphology is preferred by humans.
Collapse
Affiliation(s)
- Madoka Hattori
- Wildlife Research Center, Kyoto University, 2-24 Tanaka-Sekiden-cho, Sakyo-ku, Kyoto 606-8203, Japan
- Department of Animal Science and Biotechnology, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara-shi 252-5201, Japan
| | - Atsuko Saito
- Department of Psychology, Faculty of Human Sciences, Sophia University, 7-1 Kioicho, Chiyoda-ku, Tokyo 102-8554, Japan
| | - Miho Nagasawa
- Department of Animal Science and Biotechnology, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara-shi 252-5201, Japan
| | - Takefumi Kikusui
- Department of Animal Science and Biotechnology, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara-shi 252-5201, Japan
| | - Shinya Yamamoto
- Wildlife Research Center, Kyoto University, 2-24 Tanaka-Sekiden-cho, Sakyo-ku, Kyoto 606-8203, Japan
- Institute for Advanced Study, Kyoto University, Yoshida Ushinomiya-cho, Sakyo-ku, Kyoto 606-8501, Japan
| |
Collapse
|
8
|
Otsuka T, Adachi S, Hattori M, Sakurai Y, Tajima O. Material survey for a millimeter-wave absorber using a 3D-printed mold. Appl Opt 2021; 60:7678-7685. [PMID: 34613254 DOI: 10.1364/ao.433254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2021] [Accepted: 07/29/2021] [Indexed: 06/13/2023]
Abstract
Radio absorptive materials (RAMs) are key elements for receivers in the millimeter-wave range. We previously established a method for production of RAM by using a 3D-printed mold. An advantage of this method is a wide range of choices for absorptive materials to be used. To take advantage of this flexibility, we added a range of absorptive materials to a base epoxy resin, STYCAST-2850FT, and examined the optical performance of the resultant RAM across a wide frequency range under cryogenic conditions. We found that adding a particular type of carbon fiber produced the best performance with a reflectance at 77 K estimated as 0.01%-3% over a frequency range of 20-300 GHz.
Collapse
|
9
|
Phanthawimol W, Komatsu Y, Hattori M, Naeemah Q, Shimoo S, Ota C, Ichihara N, Kimata A, Yamasaki H, Igarashi M, Nogami A. Left coronary cusp ablation to eliminate epicardial substrates – a novel strategy for left ventricular summit ventricular tachycardia ablation. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0757] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Catheter ablation of LV summit VT can be challenging due to possible subepicardial or intramural site of origin and its close proximity to the major coronary vessels.
Objective
Local electrograms monitoring inside LV summit communicating vein potentially defines arrhythmogenic substrates and facilitates ablation from the adjacent anatomical structures.
Results
We experienced two cases of LV summit VT with epicardial local abnormal ventricular activities (Epi-LAVA) recorded from distal bipolar electrode of the 2F microcatheter in communicating vein close to the superior portion of LV summit. During sinus rhythm, Epi-LAVA displayed isolated late fractionated potentials in the first case but had initial fractionated potentials fused with terminal portion of far-field ventricular signals and late isolated potentials exhibiting 2:1 conduction in the second case. Epi-LAVA represented earliest ventricular signals during VT in both cases. Pace mapping at Epi-LAVA sites yielded single QRS morphology with excellent pacemap score and induced VT. Our strategy was to perform ablation at the facing site of Epi-LAVA aiming to eliminate the potentials transmurally. Radiofrequency (RF) energy was applied above and under the left coronary cusp opposite to Epi-LAVA sites using 3.5-mm tip open-irrigation catheter with a power of 30–35 W for 60 seconds under real-time intracardiac echocardiograhic guidance. VT was slowed and terminated in 1 second. Repeat ablation delayed and completely abolished Epi-LAVA followed by noninducibility of VT. Anatomical proximity of the left coronary cusp semilunar insertion and subepicardial or intramural site of origin possibly dictates successful ablation. Epi-LAVA from coronary vein mapping serve as a new landmark of the ablation target with a measurable procedural endpoint.
Conclusion
Elimination of epicardial substrates with RF energy application at the left coronary cusp can be a novel strategy for LV summit VT ablation.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | - Y Komatsu
- University of Tsukuba, Ibaraki, Japan
| | - M Hattori
- University of Tsukuba, Ibaraki, Japan
| | | | - S Shimoo
- University of Tsukuba, Ibaraki, Japan
| | - C Ota
- University of Tsukuba, Ibaraki, Japan
| | | | - A Kimata
- University of Tsukuba, Ibaraki, Japan
| | | | | | - A Nogami
- University of Tsukuba, Ibaraki, Japan
| |
Collapse
|
10
|
Nakanishi K, Niida H, Tabata H, Ito T, Hori Y, Hattori M, Johmura Y, Yamada C, Ueda T, Takeuchi K, Yamada K, Nagata KI, Wakamatsu N, Kishi M, Pan YA, Ugawa S, Shimada S, Sanes JR, Higashi Y, Nakanishi M. Isozyme-Specific Role of SAD-A in Neuronal Migration During Development of Cerebral Cortex. Cereb Cortex 2020; 29:3738-3751. [PMID: 30307479 DOI: 10.1093/cercor/bhy253] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2017] [Revised: 08/18/2018] [Indexed: 11/13/2022] Open
Abstract
SAD kinases regulate presynaptic vesicle clustering and neuronal polarization. A previous report demonstrated that Sada-/- and Sadb-/- double-mutant mice showed perinatal lethality with a severe defect in axon/dendrite differentiation, but their single mutants did not. These results indicated that they were functionally redundant. Surprisingly, we show that on a C57BL/6N background, SAD-A is essential for cortical development whereas SAD-B is dispensable. Sada-/- mice died within a few days after birth. Their cortical lamination pattern was disorganized and radial migration of cortical neurons was perturbed. Birth date analyses with BrdU and in utero electroporation using pCAG-EGFP vector showed a delayed migration of cortical neurons to the pial surface in Sada-/- mice. Time-lapse imaging of these mice confirmed slow migration velocity in the cortical plate. While the neurites of hippocampal neurons in Sada-/- mice could ultimately differentiate in culture to form axons and dendrites, the average length of their axons was shorter than that of the wild type. Thus, analysis on a different genetic background than that used initially revealed a nonredundant role for SAD-A in neuronal migration and differentiation.
Collapse
Affiliation(s)
- Keiko Nakanishi
- Department of Perinatology, Institute for Developmental Research, Aichi Human Service Center, Kasugai, Japan.,Department of Pediatrics, Central Hospital, Aichi Human Service Center, Kasugai, Japan
| | - Hiroyuki Niida
- Department of Cell Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.,Department of Molecular Biology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Hidenori Tabata
- Department of Molecular Neurobiology, Institute for Developmental Research, Aichi Human Service Center, Kasugai, Japan
| | - Tsuyoshi Ito
- Department of Cell Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
| | - Yuki Hori
- Department of Cell Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
| | - Madoka Hattori
- Department of Cell Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
| | - Yoshikazu Johmura
- Department of Cell Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.,Division of Cancer Cell Biology, Department of Cancer Biology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Chisato Yamada
- Department of Cell Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
| | - Takashi Ueda
- Department of Anatomy and Neuroscience, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
| | - Kosei Takeuchi
- Department of Medical Biology, Aichi Medical University, Nagakute, Aichi, Japan
| | - Kenichiro Yamada
- Department of Genetics, Institute for Developmental Research, Aichi Human Service Center, Kasugai, Japan
| | - Koh-Ichi Nagata
- Department of Molecular Neurobiology, Institute for Developmental Research, Aichi Human Service Center, Kasugai, Japan
| | - Nobuaki Wakamatsu
- Department of Genetics, Institute for Developmental Research, Aichi Human Service Center, Kasugai, Japan
| | - Masashi Kishi
- Neuroscience Laboratory, Research Institute, Nozaki Tokushukai Hospital, Daito, Osaka, Japan
| | - Y Albert Pan
- Department of Molecular and Cellular Biology and Center for Brain Science, Harvard University, Cambridge, MA, USA.,Developmental and Translational Neurobiology Center, Virginia Tech Carilion Research Institute, Roanoke, VA, USA
| | - Shinya Ugawa
- Department of Anatomy and Neuroscience, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
| | - Shoichi Shimada
- Department of Anatomy and Neuroscience, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.,Department of Neuroscience and Cell Biology, Osaka University Graduate School of Medicine, Suita, Japan
| | - Joshua R Sanes
- Department of Molecular and Cellular Biology and Center for Brain Science, Harvard University, Cambridge, MA, USA
| | - Yujiro Higashi
- Department of Perinatology, Institute for Developmental Research, Aichi Human Service Center, Kasugai, Japan
| | - Makoto Nakanishi
- Department of Cell Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.,Division of Cancer Cell Biology, Department of Cancer Biology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| |
Collapse
|
11
|
Adachi S, Hattori M, Kanno F, Kiuchi K, Okada T, Tajima O. Production method of millimeter-wave absorber with 3D-printed mold. Rev Sci Instrum 2020; 91:016103. [PMID: 32012552 DOI: 10.1063/1.5132871] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/21/2019] [Accepted: 12/27/2019] [Indexed: 06/10/2023]
Abstract
We established a production method of a millimeter-wave absorber by using a 3D-printed mold. The mold has a periodic pyramid shape, and an absorptive material is filled into the mold. This shape reduces the surface reflection. The 3D-printed mold is made from a transparent material in the millimeter-wave range. Therefore, unmolding is not necessary. A significant benefit of this production method is easy prototyping with various shapes and various absorptive materials. We produced a test model and used a two-component epoxy encapsulant as the absorptive material. The test model achieved a low reflectance: ∼1% at 100 GHz. The absorber is sometimes maintained at a low temperature condition for cases in which superconducting detectors are used. Therefore, cryogenic performance is required in terms of a mechanical strength for the thermal cycles, an adhesive strength, and a sufficient thermal conductivity. We confirmed the test-model strength by immersing the model into a liquid-nitrogen bath.
Collapse
Affiliation(s)
- S Adachi
- Division of Physics and Astronomy, Graduate School of Science, Kyoto University, Kitashirakawa-Oiwakecho, Sakyo-ku, Kyoto 606-8502, Japan
| | - M Hattori
- Astronomical Institute, Graduate School of Science, Tohoku University, 6-3, Aramaki Aza-Aoba, Aoba-ku, Sendai 980-8578, Japan
| | - F Kanno
- Astronomical Institute, Graduate School of Science, Tohoku University, 6-3, Aramaki Aza-Aoba, Aoba-ku, Sendai 980-8578, Japan
| | - K Kiuchi
- Department of Physics, Graduate School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - T Okada
- Astronomical Institute, Graduate School of Science, Tohoku University, 6-3, Aramaki Aza-Aoba, Aoba-ku, Sendai 980-8578, Japan
| | - O Tajima
- Division of Physics and Astronomy, Graduate School of Science, Kyoto University, Kitashirakawa-Oiwakecho, Sakyo-ku, Kyoto 606-8502, Japan
| |
Collapse
|
12
|
Fujioka I, Ichikawa Y, Nakajima Y, Kasahara M, Hattori M, Nemoto T. Efficiency of leukocyte depletion filters and micro-aggregate filters following intra-operative cell salvage during cesarean delivery. Int J Obstet Anesth 2019; 41:59-64. [PMID: 31358431 DOI: 10.1016/j.ijoa.2019.07.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/01/2018] [Revised: 06/07/2019] [Accepted: 07/03/2019] [Indexed: 11/18/2022]
Abstract
BACKGROUND Intra-operative cell salvage is not routinely used during cesarean delivery because it is not cost-effective for patients at low risk of hemorrhage and there are theoretical concerns about amniotic fluid embolism. Some guidelines recommend using leukocyte depletion filters to decrease the risk of amniotic fluid embolism before re-infusing salvaged blood, but these filters are not available in Japan. We compared the efficacy and safety of leukocyte depletion and micro-aggregate filters in combination with intra-operative cell salvage during cesarean delivery. METHODS Blood was collected in a Cell Saver 5 reservoir during cesarean delivery. Four samples were collected: pre-wash, post-wash, post-filtration with a leukocyte depletion filter and post-filtration with a micro-aggregate filter. Each sample was analyzed for amniotic fluid markers of zinc coproporphyrin-1 and sialyl-Tn, for fetal hemoglobin, and the sample underwent pathological examination for white blood cells and squamous cells. Post-filtration samples were compared using paired t-tests with P <0.05 indicating statistical significance. RESULTS Zinc coproporphyrin-1 and sialyl-Tn were negative at almost all sample points. Squamous cells decreased by 59.1% post-wash and 91.2% post-filtration using a leukocyte depletion filter. Leukocyte depletion filters removed 99.7% of white blood cells and were more effective in removing white blood cells than micro-aggregate filters (P=0.02). CONCLUSION Leucocyte depletion filters are more effective in removing white blood cells and squamous cells than micro-aggregate filters, and their introduction for intra-operative cell salvage during cesarean delivery should be considered in Japanese clinical practice.
Collapse
Affiliation(s)
- I Fujioka
- Department of Obstetrics and Gynecology, Japanese Red Cross Shizuoka Hospital, Japan.
| | - Y Ichikawa
- Department of Obstetrics and Gynecology, Japanese Red Cross Shizuoka Hospital, Japan
| | - Y Nakajima
- Department of Anesthesiology, Japanese Red Cross Shizuoka Hospital, Japan
| | - M Kasahara
- Department of Clinical Pathology, Japanese Red Cross Shizuoka Hospital, Japan
| | - M Hattori
- Department of Obstetrics and Gynecology, Japanese Red Cross Shizuoka Hospital, Japan
| | - T Nemoto
- Department of Obstetrics and Gynecology, Japanese Red Cross Shizuoka Hospital, Japan
| |
Collapse
|
13
|
Miura K, Harita Y, Tsurumi H, Takahashi K, Igarashi T, Iijima K, Hattori M. SUN-329 Clinical manifestations and genetic analysis of primary distal renal tubular acidosis. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
14
|
Hattori M, Shimizu A, Ishikawa O. Development of pemphigoid nodularis after remission of bullous lesions. Clin Exp Dermatol 2019; 44:e1-e2. [DOI: 10.1111/ced.13771] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/14/2018] [Indexed: 11/29/2022]
Affiliation(s)
- M. Hattori
- Department of Dermatology; Gunma University Graduate School of Medicine; 3-39-22 Showa-machi Maebashi Gunma 371 8511 Japan
- Department of Dermatology; Japan Red Cross Maebashi Hospital; Maebashi Japan
| | - A. Shimizu
- Department of Dermatology; Gunma University Graduate School of Medicine; 3-39-22 Showa-machi Maebashi Gunma 371 8511 Japan
| | - O. Ishikawa
- Department of Dermatology; Gunma University Graduate School of Medicine; 3-39-22 Showa-machi Maebashi Gunma 371 8511 Japan
| |
Collapse
|
15
|
Mori M, Sawaki M, Hattori M, Yoshimura A, Gondo N, Kotani H, Adachi Y, Kataoka A, Sugino K, Iwata H. Microdochectomy experience for patients with nipple discharge from a single institution. Breast 2019. [DOI: 10.1016/s0960-9776(19)30368-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
16
|
Yamashita T, Hattori M, Nakada T, Hayashi T, Kamei K, Tatsuya T, Nagao Y, Mase T, Wada M, Mizuno T, Shimozuma K, Iwata H, Yamaguchi T. Abstract P4-11-02: Subjective and objective assessment of efficacy of frozen gloves and socks to prevent nab-paclitaxel-induced peripheral neuropathy in patients with breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-11-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent side-effect of taxanes which play a central role in the treatment of breast cancer. CIPN can negatively influence long-term quality of life, warranting the development of effective prevention strategies. This study investigates the efficacy of frozen gloves and socks (FGS) in reducing the incidence and severity of nab-paclitaxel-induced peripheral neuropathy. Endpoints were evaluated using both clinician and patient reports.
Methods: This is a multicenter phase II single arm trial study of the effects of FGS for advanced or metastatic breast cancer patients receiving nab-paclitaxel (260 mg/m2) every 3 weeks. Patients wore FGS on their diseased side hand and foot for 60 min during infusion. The other side acted as the untreated control. CIPN was assessed using Patient Neurotoxicity Questionnaire (PNQ), PRO-CTCAE and CTCAE at baseline and every cycle of nab-paclitaxel. The primary endpoint was the incidence of CIPN assessed by PNQ (grade C or higher) after receipt of up to 4 cycles of nab-paclitaxel.
Results: Between September 2012 and January 2015, 50 patients from 16 sites were enrolled in this study. Of 50 patients, 27 (54%) received at least 4 cycles of nab-paclitaxel. There was a trend for the incidence of CIPN assessed by PNQ and PRO-CTCAE to be lower in the intervention side than in the control side, although this difference was not statistically significant. The incidence of CIPN assessed by CTCAE was significantly lower in the treated hand (Table).
Conclusions: Among breast cancer patients who received nab-paclitaxel, FGS produced favorable effects as detected by reduced clinician-reported CTCAE grades for CIPN, although the study did not detect differences in self-reported symptoms of CIPN using PRO-CTCAE or PNQ. Clinical trial information: UMIN000007907.
Difference according to the evaluation method of CIPN Hands (%) Feet (%) InterventionControlp*InterventionControlp*Patient-Reporting CIPNPNQ (grade C or higher)12190.3416160.63Patient-Reporting CIPNPRO-CTCAE Severity ≥ Moderate13180.0815160.56 Interference ≥ Somewhat7100.328100.32Clinician-Grading CIPNCTCAE (≥ Grade II)15190.0314131.0
*McNemar's test
Citation Format: Yamashita T, Hattori M, Nakada T, Hayashi T, Kamei K, Tatsuya T, Nagao Y, Mase T, Wada M, Mizuno T, Shimozuma K, Iwata H, Yamaguchi T. Subjective and objective assessment of efficacy of frozen gloves and socks to prevent nab-paclitaxel-induced peripheral neuropathy in patients with breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-11-02.
Collapse
Affiliation(s)
- T Yamashita
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - M Hattori
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - T Nakada
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - T Hayashi
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - K Kamei
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - T Tatsuya
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - Y Nagao
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - T Mase
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - M Wada
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - T Mizuno
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - K Shimozuma
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - H Iwata
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - T Yamaguchi
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| |
Collapse
|
17
|
Nawashiro Y, Shiraki K, Yamamoto S, Takizawa K, Sasada Y, Suehiro M, Miura K, Hattori M, Daikoku T, Hisano M. Persistent Primary Cytomegalovirus Infection After Deceased Donor Kidney Transplant: Ganciclovir Susceptibility of Human Cytomegalovirus With UL97 D605E Mutation: A Case Report. Transplant Proc 2018; 50:3932-3936. [PMID: 30577289 DOI: 10.1016/j.transproceed.2018.09.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Accepted: 09/05/2018] [Indexed: 11/16/2022]
Abstract
BACKGROUND Cytomegalovirus (CMV) could cause rejection in immunocompromised patients during early post-renal transplant stage. The American Transplant Society guidelines recommend prophylactic therapy with ganciclovir (GCV) for 3 to 6 months to prevent CMV infections in adult renal transplant patients. However, there is no recommended CMV treatment regimen for pediatric patients. MAIN FINDINGS We performed deceased donor kidney transplant from an anti-CMV antibody-positive donor to an anti-CMV antibody-negative 15-year-old female recipient with end-stage renal disease caused by bilateral renal hypoplasia. One month after transplant, increase in positive cells in the CMV antigenemia assay indicated a primary CMV infection in the patient, who immediately received GCV. She was switched to foscarnet after 4 months of anti-CMV therapy because of clinical GCV resistance. CMV was isolated from the peripheral blood mononuclear cells but neutralizing antibody was not detected. Isolated CMV was susceptible to GCV and foscarnet, although it carried the UL97 D605E mutation, assumed to be associated with GCV resistance. CONCLUSIONS The primary CMV infection presented a phenotypic clinical drug resistance, but all recovered CMV isolates were drug-susceptible even if isolated after prolonged anti-CMV therapy, indicating that immune status was more important for recovery from primary CMV infection than anti-CMV therapy.
Collapse
Affiliation(s)
- Y Nawashiro
- Department of Nephrology, Chiba Children's Hospital, Chiba, Japan.
| | - K Shiraki
- Department of Virology, University of Toyama, Toyama, Japan
| | - S Yamamoto
- Department of Nephrology, Chiba Children's Hospital, Chiba, Japan
| | - K Takizawa
- Department of Nephrology, Chiba Children's Hospital, Chiba, Japan
| | - Y Sasada
- Department of Nephrology, Chiba Children's Hospital, Chiba, Japan
| | - M Suehiro
- Department of Nephrology, Chiba Children's Hospital, Chiba, Japan
| | - K Miura
- Department of Pediatric Nephrology, Tokyo Women's Medical University, Tokyo, Japan
| | - M Hattori
- Department of Pediatric Nephrology, Tokyo Women's Medical University, Tokyo, Japan
| | - T Daikoku
- Department of Life Pharmacy, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan
| | - M Hisano
- Department of Nephrology, Chiba Children's Hospital, Chiba, Japan
| |
Collapse
|
18
|
Morimoto N, Shimizu A, Hattori M, Kuriyama Y, Nakano H, Ohnishi K. Dystrophic epidermolysis bullosa pruriginosa presenting with flagellate scarring lesions. Clin Exp Dermatol 2018; 44:e5-e6. [PMID: 30288768 DOI: 10.1111/ced.13803] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/01/2018] [Indexed: 11/28/2022]
Affiliation(s)
- N Morimoto
- Department of Dermatology, Japan Red Cross Maebashi Hospital, Maebashi, Japan
| | - A Shimizu
- Department of Dermatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan
| | - M Hattori
- Department of Dermatology, Japan Red Cross Maebashi Hospital, Maebashi, Japan.,Department of Dermatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan
| | - Y Kuriyama
- Department of Dermatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan
| | - H Nakano
- Department of Dermatology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
| | - K Ohnishi
- Department of Dermatology, Japan Red Cross Maebashi Hospital, Maebashi, Japan
| |
Collapse
|
19
|
Aoyama H, Ebata T, Hattori M, Takano M, Yamamoto H, Inoue M, Asaba Y, Ando M, Nagino M, Aoba T, Kaneoka Y, Arai T, Shimizu Y, Kiriyama M, Sakamoto E, Miyake H, Takara D, Shirai K, Ohira S, Kobayashi S, Kato Y, Yamaguchi R, Hayashi E, Miyake T, Mizuno S, Sato T, Suzuki K, Hashimoto M, Kawai S, Matsubara H, Kato K, Yokoyama S, Suzumura K. Reappraisal of classification of distal cholangiocarcinoma based on tumour depth. Br J Surg 2018; 105:867-875. [DOI: 10.1002/bjs.10869] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2017] [Revised: 02/22/2018] [Accepted: 03/02/2018] [Indexed: 02/02/2023]
Abstract
Abstract
Background
In the eighth edition of the AJCC cancer staging classification, the T system for distal cholangiocarcinoma (DCC) has been revised from a layer-based to a depth-based approach. The aim of this study was to propose an optimal T classification using a measured depth in resectable DCC.
Methods
Patients who underwent pancreatoduodenectomy for DCC at 32 hospitals between 2001 and 2010 were included. The distance between the level of the naive bile duct and the deepest cancer cells was measured as depth of invasion (DOI). Invasive cancer foci were measured as invasive tumour thickness (ITT). Log rank χ2 scores were used to determine the cut-off points, and concordance index (C-index) to assess the survival discrimination of each T system.
Results
Among 404 patients, DOI was measurable in 182 (45·0 per cent) and ITT was measurable in all patients, with median values of 2·3 and 5·6 mm respectively. ITT showed a positive correlation with DOI (rs = 0·854, P < 0·001), and the cut-off points for prognosis were 1, 5 and 10 mm. Median survival time was shorter with increased ITT: 12·4 years for ITT below 1 mm, 5·2 years for ITT at least 1 mm but less than 5 mm, 3·0 years for ITT at least 5 mm but less than 10 mm, and 1·5 years for ITT 10 mm or more (P < 0·001). This classification exhibited more favourable prognostic discrimination than the T systems of the seventh and eighth editions of the AJCC (C-index 0·646, 0·622 and 0·624 respectively).
Conclusion
ITT is an accurate approach for depth assessment in DCC. The four-tier ITT classification with cut-off points of 1, 5 and 10 mm seems to be a better T system than those in the seventh and eighth editions of the AJCC classification.
Collapse
Affiliation(s)
- H Aoyama
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Ebata
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Hattori
- Department of Surgery, Nishichita General Hospital, Tokai, Japan
| | - M Takano
- Department of Surgery, Asahi Rousai Hospital, Owariasahi, Japan
| | - H Yamamoto
- Department of Surgery, Tokai Hospital, Nagoya, Japan
| | - M Inoue
- Department of Surgery, Tokoname City Hospital, Tokoname, Japan
| | - Y Asaba
- Department of Surgery, JA Shizuoka Kohseiren Enshu Hospital, Hamamatsu, Japan
| | - M Ando
- Centre for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan
| | - M Nagino
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Aoba
- Toyohashi Municipal Hospital, Toyohashi
| | | | - T Arai
- Anjo Kosei Hospital, Anjo
| | - Y Shimizu
- Aichi Cancer Centre Hospital, Nagoya
| | | | - E Sakamoto
- Japanese Red Cross Nagoya Daini Hospital, Nagoya
| | - H Miyake
- Japanese Red Cross Nagoya Daiichi Hospital, Nagoya
| | - D Takara
- Kiryu Kosei General Hospital, Kiryu
| | | | | | | | - Y Kato
- Nagoya Ekisaikai Hospital, Nagoya
| | | | - E Hayashi
- Japan Community Health Care Organization Chukyo Hospital, Nagoya
| | | | - S Mizuno
- Shizuoka Welfare Hospital, Shizuoka
| | - T Sato
- Hekinan Municipal Hospital, Hekinan
| | - K Suzuki
- Japan Community Health Care Organization Kani Tono Hospital, Kani
| | | | - S Kawai
- Tsushima City Hospital, Tsushima
| | | | - K Kato
- Inazawa Municipal Hospital, Inazawa
| | | | - K Suzumura
- Shizuoka Saiseikai General Hospital, Shizuoka
| | | |
Collapse
|
20
|
Ohtani S, Yasuaki S, Takada M, Ohi Y, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M. Effectiveness of Neo-Adjuvant Systemic Therapy for Basal HER2 type Breast Cancer – Results from Retrospective Cohort Study of Japan Breast Cancer Research Group (JBCRG) – C03. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30506-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
21
|
Sumita YI, Hattori M, Murase M, Elbashti ME, Taniguchi H. Cover Image. J Oral Rehabil 2018. [DOI: 10.1111/joor.12613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
22
|
Hattori M, Nakanishi H, Yoshimura A, Adachi Y, Iwase M, Gondo N, Kotani H, Sawaki M, Yatabe Y, Iwata H. Abstract P2-01-09: Circulating tumor cells (CTCs) in the venous drainage of the breast in patients with primary breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-01-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
CTCs are shed from tumors and circulate in the peripheral blood after passing through the drainage vein. Axillary lymph node dissection (ALND) provides access to the lateral thoracic vein which flows directly into the axillary vein. In this preliminary study, we evaluated the feasibility of detecting CTCs in the peripheral blood and in the lateral thoracic venous blood for breast cancer patients who underwent ALND.
Methods:
From June 2016 to March 2017, breast cancer patients who underwent ALND in our institute were eligible for this study. A peripheral blood sample,10ml, was drawn just before the surgery or one day before the surgery. A lateral thoracic venous blood sample was taken from the resected breast just after resection. A blood sample of 0.2ml or more was necessary for CTC isolation. The CTCs in the peripheral blood before surgery (periCTC) and in the blood from the lateral thoracic vein of the resected breast (ltvCTC) were quantitatively examined by using a size-selective CTC isolation platform.
Results:
A total of 21 patients with median age 51 years (37-75) were enrolled to the study. Of the 21 patients, 38% were premenopausal, 52% had neoadjuvant chemotherapy. Fifty-seven percent were ER and/or PgR positive, 24% were HER2 positive. Fifty-seven percent were stage II disease and 43% were stage III. In 3 patients, we couldn't obtain sufficient blood samples from the lateral thoracic vein. Of the remaining 18 patients, we were able to obtain the median 0.5ml (0.2-2.0) blood samples from the lateral thoracic vein. CTCs were detected in peripheral blood in 15 patients (71%) and median periCTC count was 1 CTC/10ml (0-39). In lateral thoracic venous blood, CTCs were detected in all patients who had sufficient blood samples and the median ltv CTC count was 35.5 CTC/ml (2.5-370). In 5 of 6 patients whom CTCs in peripheral blood samples were not detected, CTCs could be detected in the blood samples from lateral thoracic vein.
Conclusion:
CTCs can be detected in the peripheral blood and in the blood from lateral thoracic vein in patients with localized breast cancer, and can be detected at a higher rate and at a higher concentration in the blood from lateral thoracic vein than in peripheral blood.
Citation Format: Hattori M, Nakanishi H, Yoshimura A, Adachi Y, Iwase M, Gondo N, Kotani H, Sawaki M, Yatabe Y, Iwata H. Circulating tumor cells (CTCs) in the venous drainage of the breast in patients with primary breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-01-09.
Collapse
Affiliation(s)
- M Hattori
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - H Nakanishi
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - A Yoshimura
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - Y Adachi
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - M Iwase
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - N Gondo
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - H Kotani
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - M Sawaki
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - Y Yatabe
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| | - H Iwata
- Aichi Cancer Center, Nagoya, Aichi, Japan; Aichi Cancer Center Aichi Hospital, Okazaki, Aichi, Japan
| |
Collapse
|
23
|
Kotani H, Terada M, Mori M, Horisawa N, Sugino K, Iwase M, Oonishi S, Kataoka A, Adachi Y, Gondou N, Yoshimura A, Hattori M, Sawaki M, Iwata H. Abstract P2-12-13: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-12-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- H Kotani
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - M Terada
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - M Mori
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - N Horisawa
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - K Sugino
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - M Iwase
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - S Oonishi
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - A Kataoka
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - Y Adachi
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - N Gondou
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - A Yoshimura
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - M Hattori
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - M Sawaki
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| | - H Iwata
- Aichi Cancer Ctr. Hosp., Nagoya, Aichi, Japan
| |
Collapse
|
24
|
Kawaguchi H, Yamashita T, Masuda N, Kitada M, Narui K, Hattori M, Yoshinami T, Matsunami N, Yanagihara K, Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, Kashiwaba M, Morita S, Ohno S, Toi M. Abstract P5-21-07: Phase II study of eribulin in combination with pertuzumab plus trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pertuzumab provided overall and progression-free survival (PFS) benefits in HER2-positive metastatic breast cancer patients (pts) in the CLEOPATRA (Clinical evaluation of docetaxel, pertuzumab and trastuzumab) study. However, few studies have described the efficacy of other drugs in combination with pertuzumab plus trastuzumab. Here, we present a pre-specified analysis of eribulin in combination with pertuzumab plus trastuzumab as first- and second-line therapy for advanced or metastatic breast cancer (AMBC) in a multicenter, open-label phase II study (UMIN000012232, JBCRG-M03).
Methods: HER2-positive AMBC with no or single prior chemotherapy for AMBC were enrolled. All pts were administered trastuzumab and taxane as adjuvant or first-line chemotherapy. Treatment consisted of eribulin 1.4 mg/m2 on days 1 and 8 of a 21-day cycle and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) plus pertuzumab (840 mg/body loading dose, then 420 mg/ body) once every 3 weeks, all administered intravenously. The primary endpoint was PFS, and secondary endpoints included overall response rate (ORR) and safety. PFS was determined using Kaplan–Meier analysis. Tumor response was assessed according to RECIST ver. 1.1.
Results: Fifty pts were enrolled from November 2013 to April 2016. Forty-nine pts were eligible for safety analysis and the full analysis set (FAS) included 46 pts. The median age was 56 years (23–70), and 8 (16%) and 41 (84%) pts were treated in first- and second-line settings, respectively. Eleven pts (23.9%) were de-novo Stage 4, and 35 pts (76.1%) had progressed in metastatic disease after completion of local therapy. Median PFS was 9.3 months (M) (95% confidence interval [CI]: 6.4–12.3). Table 1 shows the efficacy data for each treatment line and includes ORR, complete response rate (CR), partial response rate (PR), stable disease rate (SD), progressive disease rate (PD), not evaluable rate (NE) and PFS in the FAS. The median relative dose intensities of eribulin, trastuzumab, and pertuzumab were 93.3% (77.0%–100%), 100% (96.0%–100%), and 100% (89.7%–100%), respectively, in the FAS. The grade 3/4 adverse events (AE) were neutropenia in 5 pts (10.2%), including 2 pts (4.1%) with febrile neutropenia; hypertension in 3 pts (6.1%), and other AEs in only one patient. The average of the ejection fraction did not decrease significantly. Symptomatic left ventricular systolic dysfunction was not observed.
Conclusion: In pts with HER2-positive AMBC, first- and second-line therapy of eribulin in combination with pertuzumab plus trastuzumab demonstrated substantial antitumor activity with an acceptable safety profile. We are planning a phase III study comparing eribulin with taxanes in combination with pertuzumab plus trastuzumab for the treatment of HER2-positive AMBC.
Efficacy data for each treatment lineTreatment LineTotal (n=46)First line (n=8)Second line (n=38)PFS (95% CI), months9.3 (6.4-12.3)20.8 (2.8-38.7)8.7 (7.2-10.2)ORR (%)28 (60.9)7 (87.5)21 (55.3)CR (%)8 (17.4)3 (37.5)5 (13.2)PR (%)20 (43.5)4 (50.0)16 (42.1)SD (%)11 (23.9)1 (12.5)10 (26.3)PD (%)5 (10.9)05 (13.2)NE (%)2 (4.3)02 (5.3)
Citation Format: Kawaguchi H, Yamashita T, Masuda N, Kitada M, Narui K, Hattori M, Yoshinami T, Matsunami N, Yanagihara K, Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, Kashiwaba M, Morita S, Ohno S, Toi M. Phase II study of eribulin in combination with pertuzumab plus trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-07.
Collapse
Affiliation(s)
- H Kawaguchi
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - T Yamashita
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - N Masuda
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - M Kitada
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - K Narui
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - M Hattori
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - T Yoshinami
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - N Matsunami
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - K Yanagihara
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - T Kawasoe
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - T Nagashima
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - H Bando
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - H Yano
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - Y Hasegawa
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - R Nakamura
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - M Kashiwaba
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - S Morita
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - S Ohno
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - M Toi
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan; Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Osaka International Cancer Institute, Osaka, Osaka, Japan; Osaka Rosai Hospital, Osaka, Japan; Kansai Electric Power Hospital, Osaka, Japan; Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan; Chiba University Hospital, Chiba, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Hirosaki Municipal Hospital, Horosaki, Aomori, Japan; Chiba Cancer Center, Chiba, Japan; Breastopia Miyazaki Hospital, Miyazaki, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan
| |
Collapse
|
25
|
Shibata S, Ohtuka Y, Hattori M, Aoshima T, Tohyama S, Uchiyama A, Kashihara H, Tamura M, Tsuchiya A, Yoshida K, Sasamori N, Tanaka Y. Subjective Symptoms Acquisition System in a Health Promotion System for the Elderly. Methods Inf Med 2018. [DOI: 10.1055/s-0038-1634334] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
AbstractA previous report was concerned with the evaluation of quality of life using a Health Promotion System for the Elderly. In the present report, we describe one part of that system: a subjective symptoms acquisition and reporting system.The main purpose of this system is to permit any physician or nurse to uniformly employ questionnaires to acquire accurate subjective symptoms. This system is applied in three steps. First, the subjective answers to 21 questions displayed on a personal computer are obtained. These answers correspond to the basic subjective symptoms. Second, if a basic subjective symptom is “positive”, more detailed questions are automatically generated. Finally, clear sentences regarding subjective symptoms are generated and output as a “finding report”.This information is helpful to physicians and nurses in their health-counseling work. An artificial intelligence (AI) program based on “XpertRule” produces detailed questions which are generated by an interactive questionnaire using branching logical rules.
Collapse
|
26
|
Choi J, Génova-Santos R, Hattori M, Hazumi M, Ishitsuka H, Kanno F, Karatsu K, Kiuchi K, Koyano R, Kutsuma H, Lee K, Mima S, Minowa M, Nagai M, Nagasaki T, Naruse M, Oguri S, Okada T, Otani C, Rebolo R, Rubiño-Martín J, Sekimoto Y, Suzuki J, Taino T, Tajima O, Tomita N, Uchida T, Won E, Yoshida M. Status of the GroundBIRD Telescope. EPJ Web Conf 2018. [DOI: 10.1051/epjconf/201816801014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Our understanding of physics at very early Universe, as early as 10−35 s after the Big Bang, relies on the scenario known as the inflationary cosmology. Inflation predicts a particular polarization pattern in the cosmic microwave background, known as the B-mode yet the strength of such polarization pattern is extremely weak. To search for the B-mode of the polarization in the cosmic microwave background, we are constructing an off-axis rotating telescope to mitigate systematic effects as well as to maximize the sky coverage of the observation. We will discuss the present status of the GroundBIRD telescope.
Collapse
|
27
|
Sumita YI, Hattori M, Murase M, Elbashti ME, Taniguchi H. Digitised evaluation of speech intelligibility using vowels in maxillectomy patients. J Oral Rehabil 2017; 45:216-221. [PMID: 29205443 DOI: 10.1111/joor.12595] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/28/2017] [Indexed: 11/28/2022]
Abstract
Among the functional disabilities that patients face following maxillectomy, speech impairment is a major factor influencing quality of life. Proper rehabilitation of speech, which may include prosthodontic and surgical treatments and speech therapy, requires accurate evaluation of speech intelligibility (SI). A simple, less time-consuming yet accurate evaluation is desirable both for maxillectomy patients and the various clinicians providing maxillofacial treatment. This study sought to determine the utility of digital acoustic analysis of vowels for the prediction of SI in maxillectomy patients, based on a comprehensive understanding of speech production in the vocal tract of maxillectomy patients and its perception. Speech samples were collected from 33 male maxillectomy patients (mean age 57.4 years) in two conditions, without and with a maxillofacial prosthesis, and formant data for the vowels /a/,/e/,/i/,/o/, and /u/ were calculated based on linear predictive coding. The frequency range of formant 2 (F2) was determined by differences between the minimum and maximum frequency. An SI test was also conducted to reveal the relationship between SI score and F2 range. Statistical analyses were applied. F2 range and SI score were significantly different between the two conditions without and with a prosthesis (both P < .0001). F2 range was significantly correlated with SI score in both the conditions (Spearman's r = .843, P < .0001; r = .832, P < .0001, respectively). These findings indicate that calculating the F2 range from 5 vowels has clinical utility for the prediction of SI after maxillectomy.
Collapse
Affiliation(s)
- Y I Sumita
- Department of Maxillofacial Prosthetics, Graduate School, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - M Hattori
- Department of Maxillofacial Prosthetics, Graduate School, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - M Murase
- Department of Maxillofacial Prosthetics, Graduate School, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - M E Elbashti
- Department of Maxillofacial Prosthetics, Graduate School, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - H Taniguchi
- Department of Maxillofacial Prosthetics, Graduate School, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| |
Collapse
|
28
|
Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, Allemani C, Bouzbid S, Hamdi-Chérif M, Zaidi Z, Bah E, Swaminathan R, Nortje S, El Mistiri M, Bayo S, Malle B, Manraj S, Sewpaul-Sungkur R, Fabowale A, Ogunbiyi O, Bradshaw D, Somdyala N, Stefan D, Abdel-Rahman M, Jaidane L, Mokni M, Kumcher I, Moreno F, González M, Laura E, Espinola S, Calabrano G, Carballo Quintero B, Fita R, Garcilazo D, Giacciani P, Diumenjo M, Laspada W, Green M, Lanza M, Ibañez S, Lima C, Lobo de Oliveira E, Daniel C, Scandiuzzi C, De Souza P, Melo C, Del Pino K, Laporte C, Curado M, de Oliveira J, Veneziano C, Veneziano D, Latorre M, Tanaka L, Azevedo e Silva G, Galaz J, Moya J, Herrmann D, Vargas S, Herrera V, Uribe C, Bravo L, Arias-Ortiz N, Jurado D, Yépez M, Galán Y, Torres P, Martínez-Reyes F, Pérez-Meza M, Jaramillo L, Quinto R, Cueva P, Yépez J, Torres-Cintrón C, Tortolero-Luna G, Alonso R, Barrios E, Nikiforuk C, Shack L, Coldman A, Woods R, Noonan G, Turner D, Kumar E, Zhang B, McCrate F, Ryan S, Hannah H, Dewar R, MacIntyre M, Lalany A, Ruta M, Marrett L, Nishri D, McClure C, Vriends K, Bertrand C, Louchini R, Robb K, Stuart-Panko H, Demers S, Wright S, George J, Shen X, Brockhouse J, O'Brien D, Ward K, Almon L, Bates J, Rycroft R, Mueller L, Phillips C, Brown H, Cromartie B, Schwartz A, Vigneau F, MacKinnon J, Wohler B, Bayakly A, Clarke C, Glaser S, West D, Green M, Hernandez B, Johnson C, Jozwik D, Charlton M, Lynch C, Huang B, Tucker T, Deapen D, Liu L, Hsieh M, Wu X, Stern K, Gershman S, Knowlton R, Alverson J, Copeland G, Rogers D, Lemons D, Williamson L, Hood M, Hosain G, Rees J, Pawlish K, Stroup A, Key C, Wiggins C, Kahn A, Schymura M, Leung G, Rao C, Giljahn L, Warther B, Pate A, Patil M, Schubert S, Rubertone J, Slack S, Fulton J, Rousseau D, Janes T, Schwartz S, Bolick S, Hurley D, Richards J, Whiteside M, Nogueira L, Herget K, Sweeney C, Martin J, Wang S, Harrelson D, Keitheri Cheteri M, Farley S, Hudson A, Borchers R, Stephenson L, Espinoza J, Weir H, Edwards B, Wang N, Yang L, Chen J, Song G, Gu X, Zhang P, Ge H, Zhao D, Zhang J, Zhu F, Tang J, Shen Y, Wang J, Li Q, Yang X, Dong J, Li W, Cheng L, Chen J, Huang Q, Huang S, Guo G, Wei K, Chen W, Zeng H, Demetriou A, Pavlou P, Mang W, Ngan K, Swaminathan R, Kataki A, Krishnatreya M, Jayalekshmi P, Sebastian P, Sapkota S, Verma Y, Nandakumar A, Suzanna E, Keinan-Boker L, Silverman B, Ito H, Nakagawa H, Hattori M, Kaizaki Y, Sugiyama H, Utada M, Katayama K, Narimatsu H, Kanemura S, Koike T, Miyashiro I, Yoshii M, Oki I, Shibata A, Matsuda T, Nimri O, Ab Manan A, Bhoo-Pathy N, Tuvshingerel S, Chimedsuren O, Al Khater A, El Mistiri M, Al-Eid H, Jung K, Won Y, Chiang C, Lai M, Suwanrungruang K, Wiangnon S, Daoprasert K, Pongnikorn D, Geater S, Sriplung H, Eser S, Yakut C, Hackl M, Mühlböck H, Oberaigner W, Zborovskaya A, Aleinikova O, Henau K, Van Eycken L, Dimitrova N, Valerianova Z, Šekerija M, Zvolský M, Engholm G, Storm H, Innos K, Mägi M, Malila N, Seppä K, Jégu J, Velten M, Cornet E, Troussard X, Bouvier A, Faivre J, Guizard A, Bouvier V, Launoy G, Arveux P, Maynadié M, Mounier M, Fournier E, Woronoff A, Daoulas M, Clavel J, Le Guyader-Peyrou S, Monnereau A, Trétarre B, Colonna M, Cowppli-Bony A, Molinié F, Bara S, Degré D, Ganry O, Lapôtre-Ledoux B, Grosclaude P, Estève J, Bray F, Piñeros M, Sassi F, Stabenow R, Eberle A, Erb C, Nennecke A, Kieschke J, Sirri E, Kajueter H, Emrich K, Zeissig S, Holleczek B, Eisemann N, Katalinic A, Brenner H, Asquez R, Kumar V, Ólafsdóttir E, Tryggvadóttir L, Comber H, Walsh P, Sundseth H, Devigili E, Mazzoleni G, Giacomin A, Bella F, Castaing M, Sutera A, Gola G, Ferretti S, Serraino D, Zucchetto A, Lillini R, Vercelli M, Busco S, Pannozzo F, Vitarelli S, Ricci P, Pascucci C, Autelitano M, Cirilli C, Federico M, Fusco M, Vitale M, Usala M, Cusimano R, Mazzucco W, Michiara M, Sgargi P, Maule M, Sacerdote C, Tumino R, Di Felice E, Vicentini M, Falcini F, Cremone L, Budroni M, Cesaraccio R, Contrino M, Tisano F, Fanetti A, Maspero S, Candela G, Scuderi T, Gentilini M, Piffer S, Rosso S, Sacchetto L, Caldarella A, La Rosa F, Stracci F, Contiero P, Tagliabue G, Dei Tos A, Zorzi M, Zanetti R, Baili P, Berrino F, Gatta G, Sant M, Capocaccia R, De Angelis R, Liepina E, Maurina A, Smailyte G, Agius D, Calleja N, Siesling S, Visser O, Larønningen S, Møller B, Dyzmann-Sroka A, Trojanowski M, Góźdż S, Mężyk R, Grądalska-Lampart M, Radziszewska A, Didkowska J, Wojciechowska U, Błaszczyk J, Kępska K, Bielska-Lasota M, Kwiatkowska K, Forjaz G, Rego R, Bastos J, Silva M, Antunes L, Bento M, Mayer-da-Silva A, Miranda A, Coza D, Todescu A, Valkov M, Adamcik J, Safaei Diba C, Primic-Žakelj M, Žagar T, Stare J, Almar E, Mateos A, Quirós J, Bidaurrazaga J, Larrañaga N, Díaz García J, Marcos A, Marcos-Gragera R, Vilardell Gil M, Molina E, Sánchez M, Franch Sureda P, Ramos Montserrat M, Chirlaque M, Navarro C, Ardanaz E, Moreno-Iribas C, Fernández-Delgado R, Peris-Bonet R, Galceran J, Khan S, Lambe M, Camey B, Bouchardy C, Usel M, Ess S, Herrmann C, Bulliard J, Maspoli-Conconi M, Frick H, Kuehni C, Schindler M, Bordoni A, Spitale A, Chiolero A, Konzelmann I, Dehler S, Matthes K, Rashbass J, Stiller C, Fitzpatrick D, Gavin A, Bannon F, Black R, Brewster D, Huws D, White C, Finan P, Allemani C, Bonaventure A, Carreira H, Coleman M, Di Carlo V, Harewood R, Liu K, Matz M, Montel L, Nikšić M, Rachet B, Sanz N, Spika D, Stephens R, Peake M, Chalker E, Newman L, Baker D, Soeberg M, Aitken J, Scott C, Stokes B, Venn A, Farrugia H, Giles G, Threlfall T, Currow D, You H, Hendrix J, Lewis C. Erratum to “The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)” [Gynecol. Oncol. 144 (2017) 405–413]. Gynecol Oncol 2017; 147:726. [DOI: 10.1016/j.ygyno.2017.06.032] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
29
|
Fujii M, Tsunoda N, Hattori M, Murata T, Akahane K, Kamei K, Goto Y, Amemiya T, Nishimae K, Kubota T, Ito Y, Kurumiya Y, Yoshihara M, Nakanishi K, Kikumori T, Ando M, Nagino M. The efficacy of eribulin mesylate with trastuzumab for locally advanced or metastatic HER2-positive breast cancer treated with prior pertuzumab and/or T-DM1: Results from a phase II, single arm, multicenter study (N-SOG 10 study). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx654.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Hattori M, Tamura K, Mukai H, Miyoshi Y, Masuda N, Suzuki E, Ishiguro H, Ohtani S, Hara F, Shimamoto T, Yamamoto K, Ding Y, Aktan G, Karantza V, Iwata H. Phase 2 study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC): Japanese subgroup results of KEYNOTE 086. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx654.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Tanaka Y, Tsuboi T, Watanabe H, Nakatsubo D, Maesawa S, Kajita Y, Hattori M, Ohdake R, Yamamoto M, Wakabatkabayashi T, Katsuno M, Sobue G. Instability of syllable repetition in Parkinson’s disease after subthalamic nucleus deep brain stimulation. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
32
|
Shimizu A, Hattori M, Oikawa D, Amano H, Ishida-Yamamoto A, Nakano H, Sawamura D, Wakamatsu K, Tokunaga F, Ishikawa O. 210 Mechanistic insight into the repigmentation of piebaldism: Functional characterization of a mutant KIT in melanocyte regeneration. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
33
|
Kawaguchi H, Aogi K, Masuda N, Nakayama T, Ito Y, Ohtani S, Sato N, Takano T, Saji S, Tokunaga E, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer (JBCRG-C06; Safari): A subgroup analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Hattori M, Shimizu A, Oikawa D, Kamei K, Kaira K, Ishida-Yamamoto A, Nakano H, Sawamura D, Tokunaga F, Ishikawa O. Endoplasmic reticulum stress in the pathogenesis of pretibial dystrophic epidermolysis bullosa. Br J Dermatol 2017; 177:e92-e93. [DOI: 10.1111/bjd.15342] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- M. Hattori
- Department of Dermatology; Gunma University Graduate School of Medicine; Maebashi Gunma Japan
| | - A. Shimizu
- Department of Dermatology; Gunma University Graduate School of Medicine; Maebashi Gunma Japan
| | - D. Oikawa
- Laboratory of Molecular Cell Biology; Institute for Molecular and Cellular Regulation; Gunma University; Maebashi Gunma Japan
- Department of Pathobiochemistry; Graduate School of Medicine; Osaka City University; Osaka Japan
| | - K. Kamei
- Laboratory of Molecular Cell Biology; Institute for Molecular and Cellular Regulation; Gunma University; Maebashi Gunma Japan
| | - K. Kaira
- Department of Oncology Clinical Development; Gunma University Graduate School of Medicine; Maebashi Gunma Japan
| | - A. Ishida-Yamamoto
- Department of Dermatology; Asahikawa Medical University; Asahikawa Hokkaido Japan
| | - H. Nakano
- Department of Dermatology; Hirosaki University Graduate School of Medicine; Hirosaki Aomori Japan
| | - D. Sawamura
- Department of Dermatology; Hirosaki University Graduate School of Medicine; Hirosaki Aomori Japan
| | - F. Tokunaga
- Laboratory of Molecular Cell Biology; Institute for Molecular and Cellular Regulation; Gunma University; Maebashi Gunma Japan
- Department of Pathobiochemistry; Graduate School of Medicine; Osaka City University; Osaka Japan
| | - O. Ishikawa
- Department of Dermatology; Gunma University Graduate School of Medicine; Maebashi Gunma Japan
| |
Collapse
|
35
|
Hattori M, Sugino K, Yoshimura A, Sawaki M, Ishiguro J, Gondo N, Kotani H, Kataoka A, Oonishi S, Iwata H. Patient-reported assessment and objective assessment of edema among breast cancer patients receiving docetaxel plus cyclophosphamide (TC). Breast 2017. [DOI: 10.1016/s0960-9776(17)30105-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
36
|
Abstract
BACKGROUND/AIMS The human face shows morphological changes with age. Although these changes are generally recognized as wrinkle formation, there have been no quantitative studies of three-dimensional morphological changes with age in each area of the face. The object of the present study, therefore, was to evaluate age-related three-dimensional morphological changes in each area of the face. METHODS We obtained replicas using a silicon impression material from eight areas of the face (forehead, eye corners, upper eyelids, lower eyelids, glabella, cheeks, mouth angles, and nasolabial groove) of 136 healthy women, and performed morphological evaluations using a small object type three-dimensional surface morphology measurement system (Voxelan, NKK Co. Ltd., Japan). RESULTS All parameters examined, with the exception of sWvin the cheeks, increased with age. The correlation between sWp and age was high in the following order: eye corners > mouth angles > glabella > nasolabial groove > upper eyelids > lower eyelids > forehead > cheeks. sWp in all areas except the eye corners was similar to the mean value in the cheeks in the group aged 18-20 years. However, in the group aged 71-83 years, marked differences were observed among the eye corners, glabella, mouth angles, nasolabial groove, and upper eyelids. CONCLUSION Although sunlight is important in the development of three-dimensional changes in surface morphology (wrinkles) in the face, other factors seem to play important roles for the progression of these changes.
Collapse
Affiliation(s)
- Y Takema
- Biological Science Laboratories, Kao Corporation, Tochigi, Japan
| | - K Tsukahara
- Biological Science Laboratories, Kao Corporation, Tochigi, Japan
| | - T Fujimura
- Biological Science Laboratories, Kao Corporation, Tochigi, Japan
| | - M Hattori
- Biological Science Laboratories, Kao Corporation, Tochigi, Japan
| |
Collapse
|
37
|
Tanaka O, Hattori M, Hirose S, Iida T, Watanabe T. EP-1830: Comparison of the MRI sequences in ideal fiducial makerbased radiotherapy for prostate cancer. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)33081-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
38
|
Adachi N, Adamovitch V, Adjovi Y, Aida K, Akamatsu H, Akiyama S, Akli A, Ando A, Andrault T, Antonietti H, Anzai S, Arkoun G, Avenoso C, Ayrault D, Banasiewicz M, Banaśkiewicz M, Bernardini L, Bernard E, Berthet E, Blanchard M, Boreyko D, Boros K, Charron S, Cornette P, Czerkas K, Dameron M, Date I, De Pontbriand M, Demangeau F, Dobaczewski Ł, Dobrzyński L, Ducouret A, Dziedzic M, Ecalle A, Edon V, Endo K, Endo T, Endo Y, Etryk D, Fabiszewska M, Fang S, Fauchier D, Felici F, Fujiwara Y, Gardais C, Gaul W, Gurin L, Hakoda R, Hamamatsu I, Handa K, Haneda H, Hara T, Hashimoto M, Hashimoto T, Hashimoto K, Hata D, Hattori M, Hayano R, Hayashi R, Higasi H, Hiruta M, Honda A, Horikawa Y, Horiuchi H, Hozumi Y, Ide M, Ihara S, Ikoma T, Inohara Y, Itazu M, Ito A, Janvrin J, Jout I, Kanda H, Kanemori G, Kanno M, Kanomata N, Kato T, Kato S, Katsu J, Kawasaki Y, Kikuchi K, Kilian P, Kimura N, Kiya M, Klepuszewski M, Kluchnikov E, Kodama Y, Kokubun R, Konishi F, Konno A, Kontsevoy V, Koori A, Koutaka A, Kowol A, Koyama Y, Kozioł M, Kozue M, Kravtchenko O, Kruczała W, Kudła M, Kudo H, Kumagai R, Kurogome K, Kurosu A, Kuse M, Lacombe A, Lefaillet E, Magara M, Malinowska J, Malinowski M, Maroselli V, Masui Y, Matsukawa K, Matsuya K, Matusik B, Maulny M, Mazur P, Miyake C, Miyamoto Y, Miyata K, Miyata K, Miyazaki M, Molȩda M, Morioka T, Morita E, Muto K, Nadamoto H, Nadzikiewicz M, Nagashima K, Nakade M, Nakayama C, Nakazawa H, Nihei Y, Nikul R, Niwa S, Niwa O, Nogi M, Nomura K, Ogata D, Ohguchi H, Ohno J, Okabe M, Okada M, Okada Y, Omi N, Onodera H, Onodera K, Ooki S, Oonishi K, Oonuma H, Ooshima H, Oouchi H, Orsucci M, Paoli M, Penaud M, Perdrisot C, Petit M, Piskowski A, Płocharski A, Polis A, Polti L, Potsepnia T, Przybylski D, Pytel M, Quillet W, Remy A, Robert C, Sadowski M, Saito M, Sakuma D, Sano K, Sasaki Y, Sato N, Schneider T, Schneider C, Schwartzman K, Selivanov E, Sezaki M, Shiroishi K, Shustava I, Śniecińska A, Stalchenko E, Staroń A, Stromboni M, Studzińska W, Sugisaki H, Sukegawa T, Sumida M, Suzuki Y, Suzuki K, Suzuki R, Suzuki H, Suzuki K, Świderski W, Szudejko M, Szymaszek M, Tada J, Taguchi H, Takahashi K, Tanaka D, Tanaka G, Tanaka S, Tanino K, Tazbir K, Tcesnokova N, Tgawa N, Toda N, Tsuchiya H, Tsukamoto H, Tsushima T, Tsutsumi K, Umemura H, Uno M, Usui A, Utsumi H, Vaucelle M, Wada Y, Watanabe K, Watanabe S, Watase K, Witkowski M, Yamaki T, Yamamoto J, Yamamoto T, Yamashita M, Yanai M, Yasuda K, Yoshida Y, Yoshida A, Yoshimura K, Żmijewska M, Zuclarelli E. Measurement and comparison of individual external doses of high-school students living in Japan, France, Poland and Belarus-the 'D-shuttle' project. J Radiol Prot 2016; 36:49-66. [PMID: 26613195 DOI: 10.1088/0952-4746/36/1/49] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Twelve high schools in Japan (of which six are in Fukushima Prefecture), four in France, eight in Poland and two in Belarus cooperated in the measurement and comparison of individual external doses in 2014. In total 216 high-school students and teachers participated in the study. Each participant wore an electronic personal dosimeter 'D-shuttle' for two weeks, and kept a journal of his/her whereabouts and activities. The distributions of annual external doses estimated for each region overlap with each other, demonstrating that the personal external individual doses in locations where residence is currently allowed in Fukushima Prefecture and in Belarus are well within the range of estimated annual doses due to the terrestrial background radiation level of other regions/countries.
Collapse
Affiliation(s)
- N Adachi
- Adachi High School, 2-347 Kakunai, Nihonmatsu, Fukushima 964-0904, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Moteki H, Azaiez H, Booth KT, Shearer AE, Sloan CM, Kolbe DL, Nishio S, Hattori M, Usami S, Smith RJH. Comprehensive genetic testing with ethnic-specific filtering by allele frequency in a Japanese hearing-loss population. Clin Genet 2015; 89:466-472. [PMID: 26346818 DOI: 10.1111/cge.12677] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Revised: 09/06/2015] [Accepted: 09/06/2015] [Indexed: 12/31/2022]
Abstract
Recent advances in targeted genomic enrichment with massively parallel sequencing (TGE+MPS) have made comprehensive genetic testing for non-syndromic hearing loss (NSHL) possible. After excluding NSHL subjects with causative mutations in GJB2 and the MT-RNR1 (1555A>G) variant by Sanger sequencing, we completed TGE+MPS on 194 probands with presumed NSHL identified across Japan. We used both publicly available minor allele frequency (MAF) datasets and ethnic-specific MAF filtering against an in-house database of 200 normal-hearing Japanese controls. Ethnic-specific MAF filtering allowed us to re-categorize as common 203 variants otherwise annotated as rare or novel in non-Japanese ethnicities. This step minimizes false-positive results and improves the annotation of identified variants. Causative variants were identified in 27% of probands with solve rates of 35%, 35% and 19% for dominant, recessive and sporadic NSHL, respectively. Mutations in MYO15A and CDH23 follow GJB2 as the frequent causes of recessive NSHL; copy number variations in STRC are a major cause of mild-to-moderate NSHL. Ethnic-specific filtering by allele frequency is essential to optimize the interpretation of genetic data.
Collapse
Affiliation(s)
- H Moteki
- Department of Otolaryngology-Head and Neck Surgery, Molecular Otolaryngology & Renal Research Labs, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.,Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan
| | - H Azaiez
- Department of Otolaryngology-Head and Neck Surgery, Molecular Otolaryngology & Renal Research Labs, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - K T Booth
- Department of Otolaryngology-Head and Neck Surgery, Molecular Otolaryngology & Renal Research Labs, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - A E Shearer
- Department of Otolaryngology-Head and Neck Surgery, Molecular Otolaryngology & Renal Research Labs, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - C M Sloan
- Department of Otolaryngology-Head and Neck Surgery, Molecular Otolaryngology & Renal Research Labs, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - D L Kolbe
- Department of Otolaryngology-Head and Neck Surgery, Molecular Otolaryngology & Renal Research Labs, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - S Nishio
- Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan
| | - M Hattori
- Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan
| | - S Usami
- Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan
| | - R J H Smith
- Department of Otolaryngology-Head and Neck Surgery, Molecular Otolaryngology & Renal Research Labs, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| |
Collapse
|
40
|
Hattori M. Interval Cancers in Colorectal Cancer Screening, Japan—Cancer registry and Screening. Int J Epidemiol 2015. [DOI: 10.1093/ije/dyv096.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Kuriya S, Hattori M, Nagano Y, Itino T. Altitudinal flower size variation correlates with local pollinator size in a bumblebee-pollinated herb, Prunella vulgaris L. (Lamiaceae). J Evol Biol 2015; 28:1761-9. [PMID: 26174480 DOI: 10.1111/jeb.12693] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2015] [Revised: 07/02/2015] [Accepted: 07/07/2015] [Indexed: 11/30/2022]
Abstract
The influence of locally different species interactions on trait evolution is a focus of recent evolutionary studies. However, few studies have demonstrated that geographically different pollinator-mediated selection influences geographic variation in floral traits, especially across a narrow geographic range. Here, we hypothesized that floral size variation in the Japanese herb Prunella vulgaris L. (Lamiaceae) is affected by geographically different pollinator sizes reflecting different pollinator assemblages. To evaluate this hypothesis, we posed two questions. (1) Is there a positive correlation between floral length and the proboscis length of pollinators (bumblebees) across altitude in a mountain range? (2) Does the flower-pollinator size match influence female and male plant fitness? We found geographic variation in the assemblage of pollinators of P. vulgaris along an altitudinal gradient, and, as a consequence, the mean pollinator proboscis length also changed altitudinally. The floral corolla length of P. vulgaris also varied along an altitudinal gradient, and this variation strongly correlated with the local pollinator size but did not correlate with altitude itself. Furthermore, we found that the size match between the floral corolla length and bee proboscis length affected female and male plant fitness and the optimal size match (associated with peak fitness) was similar for the female and male fitness. Collectively, these results suggest that pollinator-mediated selection influences spatial variation in the size of P. vulgaris flowers at a fine spatial scale.
Collapse
Affiliation(s)
- S Kuriya
- Department of Biology, Faculty of Science, Shinshu University, Matsumoto, Nagano, Japan
| | - M Hattori
- Department of Biology, Faculty of Science, Shinshu University, Matsumoto, Nagano, Japan
| | - Y Nagano
- Department of Biology, Faculty of Science, Shinshu University, Matsumoto, Nagano, Japan
| | - T Itino
- Department of Biology, Faculty of Science, Shinshu University, Matsumoto, Nagano, Japan.,Institute of Mountain Science, Shinshu University, Matsumoto, Nagano, Japan
| |
Collapse
|
42
|
Ito Y, Miyashiro I, Hattori M, Nishino Y, Ioka A, Nakayama T, Rachet B. P0095 Trends in cure proportion of major cancer sites in Japan between 1993 and 2006 (J-CANSIS study): An observational study. Eur J Cancer 2015. [DOI: 10.1016/j.ejca.2015.06.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
43
|
Elbashti ME, Hattori M, Sumita YI, Taniguchi H. Evaluation of articulation simulation system using artificial maxillectomy models. J Oral Rehabil 2015; 42:678-84. [PMID: 25975670 DOI: 10.1111/joor.12306] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/18/2015] [Indexed: 10/23/2022]
Abstract
Acoustic evaluation is valuable for guiding the treatment of maxillofacial defects and determining the effectiveness of rehabilitation with an obturator prosthesis. Model simulations are important in terms of pre-surgical planning and pre- and post-operative speech function. This study aimed to evaluate the acoustic characteristics of voice generated by an articulation simulation system using a vocal tract model with or without artificial maxillectomy defects. More specifically, we aimed to establish a speech simulation system for maxillectomy defect models that both surgeons and maxillofacial prosthodontists can use in guiding treatment planning. Artificially simulated maxillectomy defects were prepared according to Aramany's classification (Classes I-VI) in a three-dimensional vocal tract plaster model of a subject uttering the vowel /a/. Formant and nasalance acoustic data were analysed using Computerized Speech Lab and the Nasometer, respectively. Formants and nasalance of simulated /a/ sounds were successfully detected and analysed. Values of Formants 1 and 2 for the non-defect model were 675.43 and 976.64 Hz, respectively. Median values of Formants 1 and 2 for the defect models were 634.36 and 1026.84 Hz, respectively. Nasalance was 11% in the non-defect model, whereas median nasalance was 28% in the defect models. The results suggest that an articulation simulation system can be used to help surgeons and maxillofacial prosthodontists to plan post-surgical defects that will be facilitate maxillofacial rehabilitation.
Collapse
Affiliation(s)
- M E Elbashti
- Department of Maxillofacial Prosthetics, Graduate School, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - M Hattori
- Department of Maxillofacial Prosthetics, Graduate School, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - Y I Sumita
- Department of Maxillofacial Prosthetics, Graduate School, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - H Taniguchi
- Department of Maxillofacial Prosthetics, Graduate School, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| |
Collapse
|
44
|
Abstract
The dorsal resting hair of C3H mice at various ages was shaved, thus activating the hair into the anagen stage. New hair growth after shaving was not uniform in the various age groups. Furthermore, an increasing delay in hair regrowth was observed as the mice became older (20, 66, 188, and 312 days). In the biochemical analysis of hair regrowing and nongrowing skins after shaving, activities of ornithine decarboxylase, transglutaminase, and alkaline phosphatase had higher values in the extract of the hair regrowing area compared with that in the nongrowing area. In studying the effects of various physical and chemical treatments on hair growth after shaving, repeated shaving was in itself clearly shown to stimulate hair growth. Amongst all of the treatments that were applied, topical application of TPA was most able to accelerate hair regrowth, followed by UV irradiation and retinoic acid treatment. Suppression of hair regrowth was observed in PUVA, DHT, and estradiol; and complete inhibition was seen in the animals treated with betamethasone valerate. In biochemical studies, a relatively good correlation was observed between the rate of hair regrowth and skin ODC activities after treatment.
Collapse
|
45
|
Ogawa H, Manabe M, Hirotani T, Takamori K, Hattori M. Comparative studies of the marginal band and plasma membrane of the epidermis. Curr Probl Dermatol 2015; 11:265-76. [PMID: 6197246 DOI: 10.1159/000408681] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The membranous fraction isolated from stratum corneum by 8M urea-beta ME containing alkaline buffer (pH 9.0) is quite crude when observed by electron microscopy. However, this procedure may be useful for clinical samples, as one can isolate and compare both the soluble (interfilamentous) fraction and the keratin filament from the same sample in addition to the residues (membranous fraction). A further purified membranous fraction was isolated by a new method. Human stratum corneum was chopped and treated with 8M urea-50 mM Tris-HCl (pH 9.0), digested by the use of trypsin, and the product fractionated by a sucrose density gradient to obtain separate single cells without the cytoplasm. One sample was then treated with trypsin for 1 hour and another with urea buffer for 24 hours. Observations revealed a thickened inner membrane (marginal band) of approximately 150A. Each of the membranous samples contained a level of half-cystine markedly higher in amount (around 100/1,000) and involved mostly in the epsilon-(gamma-glutamyl) lysine cross-linkages (around 30%). In order to compare the membranous fraction of horny and living cells (marginal bands and plasma membranes), the fraction was then isolated from living cells. The relative amino acid composition of the membranous fraction of the plasma membrane resembled that of human erythrocytes, but was quite different from that of the marginal band. These comparative studies of biochemical and morphological features suggested the importance of S-S cross-linking enzymes and transglutaminase in the transformation mechanism of the marginal band.
Collapse
|
46
|
Hattori M, Ogawa H. Characteristics of fibrous protein and the disulphide cross-linking bond in human stratum corneum. Curr Probl Dermatol 2015; 10:379-90. [PMID: 6165529 DOI: 10.1159/000396302] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Fibrous proteins of human stratum corneum were isolated with urea-Tris buffer (pH 9.0) with and without 2-mercaptoethanol (2ME). Comparative studies were made of the biochemical and morphological properties of purified samples obtained with and without 2ME. The final yield of fibrous protein extracted with 2ME was 17 times higher than the yield extracted without 2ME. Identical results were found for the 2 samples by electron microscopic observation, SDS gel electrophoresis with urea and 2ME, and amino acid analysis. However, high molecular weight staining patterns appeared on the SDS gel when the fibrous protein extracted without 2ME was treated with sample buffer containing 4 M urea but no 2ME. These staining patterns were indicative of cross-linking with disulphide bonds. Extraction of the structural proteins with or without 2ME produced the same amount of polymerized fibrous protein. These results suggested that the structural polypeptides of fibrous protein were constructed through ionic forces rather than disulphide bonds. Electron microscopic observation also did not show any differences in the fibrous structures constructed with or without 2ME. The structural polypeptide molecules, than, may be stabilized by partial cross-linking with disulphide bonds. It is possible that the addition of 2ME cleaves disulphide bonds in cell membrane structures and releases fibrous components more effectively than the addition of agents which physically disrupt membrane structures. Consequently, the increase of yield of fibrous protein by the addition of 2ME might be mainly due to cleaving of the membrane structures and partially due to cleaving interpolypeptide disulphide bonds.
Collapse
|
47
|
Kotani H, Kondou N, Ishiguro J, Hisada T, Adachi Y, Ichikawa M, Yoshimura A, Hattori M, Sawaki M, Iwata H. P130 Investigation by questionnaire of the employment of Japanese breast cancer patients. Breast 2015. [DOI: 10.1016/s0960-9776(15)70172-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
48
|
Hattori M, Fujita T, Sawaki M, Kondou N, Yoshimura A, Ichikawa M, Ishiguro J, Iwata H. P104 Patterns of recurrence and survival in HER2+ patients relapsing after receiving adjuvant trastuzumab. Breast 2015. [DOI: 10.1016/s0960-9776(15)70148-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
49
|
Fujita T, Sawaki M, Hattori M, Kondou N, Yoshimura A, Gondou N, Ichikawa M, Kotani H, Adachi Y, Hisada T, Ishiguro J, Iwata H. Risk of Locoregional Recurrence After Mastectomy By Hormone Receptor Status and Her2 Status in Breast Cancer Patients with 1-3 Positive Nodes. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu328.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Fujita T, Sawaki M, Hattori M, Naoto K, Horio A, Gongou N, Ichikawa M, Idota A, Adachi Y, Hisada T, Kotani H, Ishiguro J, Iwata H. Abstract P5-14-02: Postmastectomy radiation improves loco-regional control for patients with advanced breast cancer treated with neoadjuvant chemotherapy. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-14-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose
The value of postmastectomy radiation (PMRT) with adjuvant chemotherapy has been established, but the role of PMRT after neoadjuvant chemotherapy remains unclear.
The aim of this study was to evaluate the efficacy of radiation in patients treated with neoadjuvant chemotherapy and mastectomy, and to determine which subsets of patients benefit from PMRT.
Patients and Methods
From 2003 to 2008, 94 patients were treated with neoadjuvant chemotherapy and mastectomy. The median number of lymph nodes removed was 20. 90 patients received anthracycline-based (anthracycline alone: 5, anthracycline followed by taxane: 85) chemotherapy and 4 patients received taxane alone. 82.6 percent (19/23) of the patients with HER2 positive cancer received trastuzumab and 91.3 percent (63/69) of the patients with hormone receptor positive cancer received hormone therapy. In this study, pathological complete response (pCR) was defined as absence of invasive tumor in the breast.
We compared the outcomes of 55 patients who received radiation (PMRT group) from 39 patinets who did not receive radiation (non-PMRT group).
The 5 years rate of loco-regional recurrence (LRR) was calculated according to the Kaplan-Meier method, and comparisons between the two groups were made using the log-rank test.
Results
Median follow-up time was 61.8 months. The breast pCR rate was 17.0% (16/94). 14 patients developed LRR as first events (local: 8, regional: 4, local and regional: 2). There were no differences between the two groups with respect to age, use of trastzumab, use of hormone therapy, pathological tumor size, number of dissected axillary nodes, percentage of hormone receptor positive tumors, or HER2 positive tumors.
The 5-years rate of LRR for the PMRT group and the non-PMRT group were 12.8% and 27.0% respectively. (p = 0.144) In the patients with positive lymph nodes after neoadjuvant chemotherapy, the PMRT group had significantly lower LRR risk than the non-PMRT group (5-yaers rate: 11.9% vs 37.5%, p = 0.039). But in the patients with negative lymph node, there were no significant difference between the PMRT group and the non-PMRT group. For hormone receptor positive and HER2 negative subtype, a significantly improved LRR risk found after PMRT (5-yaers rate: 5.9% vs 26.1%, p = 0.048). No significant difference in HER2 positive subtype and triple negative subtype were observed between two groups. In the patients who did not achieve breast pCR, the PMRT group had significantly lower LRR risk than the non-PMRT group (5-yaers rate: 9.0% vs 30.6%, p = 0.037). The 5-years rate of lymphedema was no significant difference between the two groups (p = 0.787).
Conclusion
After neoadjuvant chemotherapy and mastectomy, PMRT was found to benefit local control for the patients with positive lymph nodes, the patients with hormone receptor positive and HER2 negative cancer, and the patients who did not achieve breast pCR.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-14-02.
Collapse
Affiliation(s)
- T Fujita
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - M Sawaki
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - M Hattori
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - K Naoto
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - A Horio
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - N Gongou
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - M Ichikawa
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - A Idota
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - Y Adachi
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - T Hisada
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - H Kotani
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - J Ishiguro
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - H Iwata
- Aichi Cancer Center Hospital, Nagoya, Japan
| |
Collapse
|